Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-04-02Clinical Trial Update: Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer [Phase 2]
Phase 2 study evaluating a conditioning regimen of fludarabine phosphate, cyclophosphamide, and total body irradiation followed by donor ste…
-
CLINICAL_TRIALS trial_result · 2024-03-25Clinical Trial Update: Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating Umbilical Cord Blood-derived CAR-engineered NK cells for B lymphoid malignancies has completed with po…
-
CLINICAL_TRIALS trial_result · 2024-03-19Clinical Trial Update: Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients [Phase 2]
Phase II open-label trial evaluating tisagenlecleucel in pediatric non-Hodgkin lymphoma has completed and posted results in March 2024, asse…
-
CLINICAL_TRIALS trial_result · 2024-03-06Clinical Trial Update: Chidamide Bridging for CAR-T Therapy [Phase 1, Phase 2]
Clinical trial update on chidamide bridging for CAR-T therapy in Non-Hodgkin's Lymphoma (Phase 1/Phase 2).
-
CLINICAL_TRIALS trial_result · 2024-02-20Clinical Trial Update: PROACT: Can we Prevent Chemotherapy-related Heart Damage in Patients With Breast Cancer and Lymphoma? [Phase 3]
Phase 3 trial update investigating PROACT to prevent chemotherapy-related heart damage in patients with breast cancer and non-Hodgkin lympho…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-02-14Clinical Trial Update: DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL [Phase 2]
Phase 2 trial evaluating DA-EPOCH-R induction followed by nivolumab consolidation in newly diagnosed high-grade B-cell lymphoma with MYC, BC…
-
CLINICAL_TRIALS trial_result · 2024-02-14Clinical Trial Update: Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood Cancer [Phase 2]
Phase 2 trial evaluating romiplostim to treat low platelets after chemotherapy and autologous hematopoietic cell transplantation in people w…
-
FDA approval · 2024-02-08FDA Approved: VIVIMUSTA — Supplemental Application (Azurity Pharmaceuticals, Inc.)
The FDA approved a supplemental application for VIVIMUSTA (bendamustine hydrochloride) filed by Azurity Pharmaceuticals, Inc., to update/exp…
-
FDA approval · 2024-02-05FDA Approved: PLERIXAFOR — Supplemental Application (Meitheal Pharmaceuticals Inc.)
The FDA approved a supplemental application for Plerixafor by Meitheal Pharmaceuticals, granting approval for an additional submission relat…
-
CLINICAL_TRIALS trial_result · 2024-02-02Clinical Trial Update: A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma [Phase 1]
Phase 1b open-label study evaluating safety and pharmacokinetics of subcutaneous blinatumomab in relapsed/refractory indolent non-Hodgkin's …
-
CLINICAL_TRIALS trial_result · 2024-02-01Clinical Trial Update: Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL) [Phase 2]
The phase 2 TIDAL trial of Zandelisib (ME-401) in follicular lymphoma, non-Hodgkin lymphoma, and marginal zone lymphoma was terminated, with…
-
CLINICAL_TRIALS trial_result · 2024-02-01Clinical Trial Update: Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. [Phase 1]
Phase 1 study of pembrolizumab plus vorinostat in relapsed or refractory B-cell lymphomas and classic Hodgkin lymphoma; results posted in Fe…
-
CLINICAL_TRIALS trial_result · 2024-01-31Clinical Trial Update: CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant [Phase 1]
Phase 1 trial evaluating the CMV-MVA Triplex vaccine given to stem cell donors to prevent cytomegalovirus viremia in recipients of allogenei…
-
FDA approval · 2024-01-30FDA Approved: PLERIXAFOR — Supplemental Application (Dr. Reddy's Laboratories Inc)
FDA approved a supplemental application for plerixafor from Dr. Reddy's Laboratories, typically resulting in a labeling or usage modificatio…
-
FDA approval · 2024-01-30FDA Approved: PLERIXAFOR — Supplemental Application (Zydus Lifesciences Limited)
FDA approves a supplemental application for Plerixafor submitted by Zydus Lifesciences Limited.
-
CLINICAL_TRIALS trial_result · 2024-01-30Clinical Trial Update: Vaccination With Flt3L, Radiation, and Poly-ICLC [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating vaccination with Flt3L, radiation, and Poly-ICLC in cancer patients.
-
CLINICAL_TRIALS trial_result · 2024-01-23Clinical Trial Update: APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A clinical trial update for APG-1252 as monotherapy or in combination for relapsed or refractory non-Hodgkin lymphoma is in Phase 1/Phase 2,…
-
CLINICAL_TRIALS trial_result · 2024-01-16Clinical Trial Update: Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies [Phase 1, Phase 2]
Early-phase study of CB-103 in adults with various advanced solid tumors and hematologic malignancies has been terminated; results were post…
-
FDA approval · 2024-01-11FDA Approved: BELRAPZO — Supplemental Application (Eagle Pharmaceuticals, Inc)
The FDA approved a supplemental application for Belrapzo (bendamustine hydrochloride) submitted by Eagle Pharmaceuticals, Inc. The action up…
-
CLINICAL_TRIALS trial_result · 2024-01-10Clinical Trial Update: A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating Betalutin in relapsed non-Hodgkin lymphoma has completed. The study included follicular lymphoma, with r…
-
CLINICAL_TRIALS trial_result · 2023-12-27Clinical Trial Update: Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 trial evaluating combination chemotherapy plus rituximab in recurrent or refractory non-Hodgkin's lymphoma.
-
CLINICAL_TRIALS trial_result · 2023-12-27Clinical Trial Update: Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 trial updating the use of colony-stimulating factors to relieve neutropenia in patients with recurrent non-Hodgkin's lymphoma.
-
CLINICAL_TRIALS trial_result · 2023-12-27Clinical Trial Update: Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Stage III or Stage IV Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 trial evaluating vaccine therapy plus sargramostim following chemotherapy in Stage III/IV non-Hodgkin's lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2023-12-22Clinical Trial Update: Study of Safety and Efficacy of Betalutin and Rituximab in Patients With FL [Phase 1]
Phase 1 clinical trial update on safety and efficacy of betalutin with rituximab in follicular lymphoma, completed with posted results in 20…
-
CLINICAL_TRIALS trial_result · 2023-12-13Clinical Trial Update: Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) [Phase 3]
Phase 3 trial COASTAL evaluating Zandelisib in combination with Rituximab in indolent non-Hodgkin lymphoma was terminated; results were post…